OTEZLA® (Apremilast) Showed Meaningful Improvements in Clinical and Quality-of-Life Measures of Psoriasis Beyond Those Captured by Assessing Skin Alone

Patients with moderate to severe plaque psoriasis showed meaningful improvements in skin, itch and quality-of-life measures among PASI 75 non-responders treated with OTEZLA, according to a post hoc sub-analysis of data from the phase 3 ESTEEM 1 trial Findings suggest a broad assessment of skin lesions, itching and quality of life may offer meaningful benefit with OTEZLA therapy in patients with moderate to severe plaque psoriasis A separate post hoc sub-analysis of data from the phase 3 ESTEEM 1 and 2 and phase 4 UNVEIL trials showed improvement in areas such as the scalp and nails with OTEZLA versus placebo